Core Viewpoint - Sunshine Nuohong (688621.SH) has announced the termination of its acquisition of Jiangsu Langyan Life Science Technology Co., Ltd., marking the second time the company has halted this acquisition process, revealing multiple concerns regarding its strategic execution, corporate governance, and integration of targets [1] Group 1: Strategic Fluctuations - The acquisition of Langyan Life has faced significant challenges, with the initial launch in October 2022, a termination in August 2023 due to "market environment changes," a restart in April 2025, and another termination shortly thereafter, raising doubts about the company's strategic consistency and decision-making rigor [2][7] - The company's performance in 2024 showed "increased revenue without increased profit," making the acquisition a critical move for expanding the industrial chain and enhancing production synergy, but the repeated halts indicate a clear obstruction in achieving vertical integration through mergers and acquisitions [2][7] Group 2: Related Transactions and Valuation Concerns - The transaction involves a conflict of interest as the controlling shareholder of Sunshine Nuohong, Li Qian, is also the controlling shareholder of Langyan Life, leading to concerns about potential profit transfer despite the company’s assurances of a profit compensation mechanism [2][7] - Langyan Life's revenue has fluctuated significantly from 510 million yuan in 2021 to 231 million yuan in the first half of 2025, with net profits varying between 20 million and 80 million yuan, raising questions about the sustainability of the optimistic profit forecasts for 2025-2030 against the backdrop of a 1.2 billion yuan valuation [3][8] Group 3: Performance Volatility and Synergy Realization - Langyan Life specializes in high-end chemical drug formulations and raw material production, which, while related to Sunshine Nuohong's CRO business, differ in operational logic, making the anticipated integration and synergy uncertain given the target company's unstable performance and changing industry policies [4][9] - Sunshine Nuohong's own performance has also entered a volatile phase, with a decline in net profit in 2024, and while growth is forecasted for 2025, it is primarily driven by licensing agreements, indicating that the sustainability of core business growth remains to be seen [4][9] Group 4: Conclusion on Caution vs. Hesitation - The repeated termination of the acquisition reflects Sunshine Nuohong's cautious approach in navigating the transaction amidst variable market conditions and target performance, while also indicating potential areas for improvement in strategic execution, due diligence, and risk assessment [5][10] - Investors should monitor whether the company will attempt to restart the acquisition for a third time, as well as the transparency of its corporate governance, the coherence of its strategic deployment, and its ability to build a sustainable profit moat in its core business [5][10]